Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®.

Gilde followed Affimed’s development for many years and became convinced about the potential of its technology platform and immune oncology product pipeline. By anchoring an upsized public offering of $103.5 million in April 2022, we enabled a transformational financing in a turbulent market environment, reflecting our impactful, hands-on investment strategy.